

PRESS NEWS

Gradientech announces Notice of Allowance from Chinese Patent Office

Uppsala, March 20, 2019. Gradientech AB, a Swedish biotech and diagnostic company developing the next generation ultra-rapid antibiotic susceptibility testing (AST) system for appropriate treatment of sepsis, today announces that the Company has received a Notice of Allowance from the Chinese Patent Office (CHN) for the patent application no. 201480038696, "New Use of a Fluidic Device". The patent application covers the proprietary minimum inhibitory concentration (MIC) determination of a bacterial sample within a microfluidic controlled environment that is part of the technology platform of the Company's diagnostic system QuickMIC™ for ultra-rapid AST. A Notice of Allowance signifies that Gradientech will be entitled to receive patent protection until 2034 in China for the allowed claims when the patent is issued. Gradientech has already been granted patent protection for MIC determination in Europe and Japan.

For further information, please contact:

Sara Thorslund, CEO

Tel: +46 736 29 35 80, email: sara.thorslund@gradientech.se

TO THE EDITORS

About Gradientech AB

Gradientech is a Swedish biotech and diagnostic company focusing on innovative microfluidic product development. We provide systems for high-quality analysis of cell behaviour in response to gradients of biomolecules. Gradientech is currently developing QuickMIC™, an ultra-rapid system for antibiotic susceptibility testing. QuickMIC is designed to offer personalized treatment options for sepsis patients, thereby contributing to increased survival, reduced healthcare costs and lower antibiotic resistance. www.gradientech.se